TriangleNavlimetostat + Pumitamig (NCT07579221)
Navlimetostat + Pumitamig trial for MTAP-Deleted Advanced Non-Small Cell Lung Cancer (NCT07579221). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with advanced non-small cell lung cancer whose tumors lack a gene called MTAP.
The idea: combine navlimetostat, a pill taken once a day, with pumitamig, given by infusion. Tumors that lack MTAP may be especially sensitive to navlimetostat.
The study looks for a safe dose of the combination, and at how well it works.
This phase 1 and 2 study plans 17 patients. At MD Anderson Cancer Center in Houston, Natalie Vokes leads it.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.